Phase 2 Non-Alcoholic Fatty Liver Disease Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who carry two copies of a specific gene variant called PNPLA3 p.I148M (one inherited from each parent)
• People whose liver contains 15% or more fat, as measured by a specific type of MRI scan called MRI-PDFF
• People with a Body Mass Index (BMI) of 30 or above but below 45 (a measure of body weight relative to height)
• For one part of the trial (Part A): People whose liver enzyme levels (ALT and AST) are within an acceptable range as set out in the trial protocol
• For one part of the trial (Part A): People who are already taking a stable dose of the medication tirzepatide (at least 5 mg weekly) at the time of joining

Who may not be able to join:

• People who have been diagnosed with, or show signs of, high blood pressure in the liver (portal hypertension) or severe liver scarring (cirrhosis), from any cause
• People who have a known long-term liver condition other than a specific fat-related liver disease called MASLD
• People for whom MRI scans are not safe or suitable — for example, those with certain types of pacemakers or metal implants in the body, severe fear of enclosed spaces, or body size that makes MRI scanning difficult
• People for whom tirzepatide (Zepbound) is medically unsuitable, based on the official prescribing guidelines for that medication in the United States

Important: Always verify eligibility with the trial site directly before applying.